NCT03829436 2023-07-03
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
Phase 1 Completed
Tempest Therapeutics
Bristol-Myers Squibb
Nektar Therapeutics
Presage Biosciences
Oncovir, Inc.